The Pharmacological Management of Essential Tremor and Its Long-Term Effects on Patient Quality of Life: A Systematic Review.

Authors: Alharbi O, Albaibi SA, Almutairi AA, Alsaqabi E, Alharbi M, Alharbi BS, Almansour MF, Al-Qahtani ZA

Essential tremor (ET) is one of the most prevalent nerve-related movement disorders, most commonly affecting the hands during voluntary movements or while maintaining posture. Unlike tremors in neurodegenerative conditions, ET is not observed at rest. Continued research is essential to optimize treatment strategies and address the unmet need for sustainable, patient-centered therapies that minimize side effects and enhance long-term quality of life (QoL) for individuals with ET. Five medical databases were searched for content relevant to this study's topic, utilizing the guidelines set forth by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). These databases searched include Web of Science, PubMed, Cochrane Library, ScienceDirect, and Google Scholar for publications between 2010 and 2024. The review analyzed studies including adult patients with ET, focusing on efficacy, safety, and QoL outcomes, with priority given to studies from the Middle East or Saudi Arabia. We included 10 studies that met our inclusion criteria for a full review. Based on the studies, pharmacological treatments such as alprazolam, primidone, propranolol, and CX-8998 were found to be efficient in the management of ET. Emerging medications, including CX-8998 and alprazolam, showed mixed results with significant adverse events. Surgical interventions like deep brain stimulation (DBS) demonstrated long-term motor control benefits, although functional declines occurred due to disease progression. Novel approaches like low-intensity focused ultrasound (LIFU), transcutaneous afferent patterned stimulation (TAPS), and incobotulinumtoxinA injections presented promising results with improved tremor control and minimal side effects. In conclusion, pharmacological treatments for ET provide symptomatic relief but are limited by side effects and reduced long-term efficacy, significantly impacting QoL. Surgical and novel therapeutic options offer enhanced motor control and durability of effects, though they are not universally applicable.

Introduction

Purpose Transcranial ultrasound stimulation

Study Objective To systematically review and evaluate the efficacy, safety, and quality-of-life outcomes of pharmacological treatments for essential tremor, with priority given to studies from the Middle East and Saudi Arabia.

Animal model / Human subject Homo sapiens (human), N/A strain, adults, both sexes (mixed/unspecified)

Disease model Essential tremor

Cargo name and characteristics Alprazolam — small molecule (benzodiazepine); Primidone — small molecule (anticonvulsant); Propranolol — small molecule (non-selective beta-adrenergic blocker); CX-8998 — small molecule (experimental centrally acting/T-type calcium channel modulator); IncobotulinumtoxinA — protein (botulinum neurotoxin type A formulation)

Route of administration injections

Outcomes and Safety

Summary of Outcomes Pharmacological treatments (propranolol, primidone, alprazolam, CX-8998) produced symptomatic tremor reduction but were limited by side effects and declining long-term efficacy; surgical (DBS) and novel interventions (low‑intensity focused ultrasound, transcutaneous afferent patterned stimulation, incobotulinumtoxinA) provided improved and more durable motor control with fewer adverse effects. No specific LIFU focused‑ultrasound parameter sets were reported or compared in the included studies.

Safety-related matter Pharmacological treatments (e.g., alprazolam, primidone, propranolol, CX-8998) were effective but limited by side effects, tolerability/adherence issues, and emerging agents (CX-8998, alprazolam) showed mixed results with significant adverse events; DBS provided long-term motor control though functional decline occurred from disease progression, while novel therapies (LIFU, TAPS, incobotulinumtoxinA) demonstrated promising tremor control with minimal/reduced side effects.

Brain Region

Visualization unavailable

Ultrasound Parameters

Focal Characteristics Focal depth: None; Focal length: None; Aperture size: None

Treatment frequency multiple sessions

We are open to feedback. If you see a mistake or have a suggestion, please contact us.